PARP Inhibitors in development

LEERINK SWANN

Drug	Company	Development Stage	Upcoming Catalyst	Data	Indication
Iniparib (BSI201)	Sanofi-Aventis	Phase 3	Failed	OS - 11.1mon (GC, 258pts) vs. 11.8mon (IGC, 261pts), PFS - 4.1mon (GC) vs. 5.1mon (IGC)	
Niraparib (MK-4827)	Tesaro/Merck	Phase 1	Phase 2 in 2013	Ph1 (80pts) - 37% RR in BRCA+ pts, bone-marrow toxicity	Solid tumor
Rucaparib (PF01367338)	Clovis/Pfizer	Phase 1	Data in 1H14		
Olaparib (AZD2281)	AstraZeneca	Phase 2	Data in mid-12	Study 1 monotherapy (136 & 129pts) - PFS 8.4 vs. 4.8mon, OS 29.7 vs. 29.9mon; Study 2 chemo-combo therapy (66 & 55pts) - PFS 12.2 (OPC) vs. 9.6mon (PC), OS NA	maintenance therapy in serous ovarian cancer
Veliparib (ABT888)	Abbott	Phase 2	Data in 2H13	Partial RR 20%	Advanced colon cancer and other solid tumors
CEP-9722	Cephalon/Teva	Phase 2	Data in mid-13		
BMN673 (LT-673)	Biomarin	Phase 1	Data in 2H13 and 1Q13	No significant toxicity, high potent (100ug activity dose)	BRCA1/2+ ovarian cancer
E-7016	Eisai	Phase 1	Data in 3Q12 and 1H14		
BSI401	BiPar Science				

Source: Company reports, ClinicalTrial.gov, and Leerink Swann